Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HK 660S

Next Previous
X
Search
Drug Profile

HK 660S

Alternative Names: Beta-Lapachone; HK-660-S

Latest Information Update: 14 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CUROME BIOSCIENCES
  • Class Anti-inflammatories; Antifibrotics; Antineoplastics; Eye disorder therapies; Naphthoquinones; Obesity therapies; Small molecules
  • Mechanism of Action NQO1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Primary sclerosing cholangitis

Most Recent Events

  • 05 Jun 2024 Efficacy, Adverse events and pharmacodynamics data from a phase II trial in Primary sclerosing cholangitis presented at the European Association for the Study of the Liver Congress 2024 (EASL-2024)
  • 24 Jul 2023 CuromeBiosciences completes a phase II trial in Primary sclerosing cholangitis in South Korea (PO) (NCT05866809)
  • 01 Apr 2022 HK 660S receives Orphan Drug status for Primary sclerosing cholangitis in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top